PTGDR
ENSG00000168229
Target class
GPCR
Chromosome
14
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- PTGDR
- Gene name
- Prostaglandin D2 receptor
- Gene symbol
- PTGDR
- Protein name
- Prostaglandin D2 receptor (PGD receptor) (PGD2 receptor) (Prostanoid DP receptor)
- DP
- DP1
- PTGDR1
- Gene biotype
- Protein coding
- Gene family
- Prostaglandin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 20
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 8.18
- Tissue specificity (Gini)
- 0.582
- Tissue specificity (tau)
- 0.852
- KEGG gene identifiers
- hsa:5729
- Protein interaction confidence
- 0.804167
- Protein interaction partners
- 6
- R-HSA-391908
- R-HSA-418555
- End position
- 52276724
- Start position
- 52267698
- Chromosome
- 14
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.851917
- Expression inequality (Gini)
- 0.581944
Expression in transcripts per million
- Spleen
- 8.18
- Colon - Transverse
- 6.68
- Cervix - Ectocervix
- 4.84
- Nerve - Tibial
- 4.18
- Cervix - Endocervix
- 4.1
Expression in transcripts per million
- Spleen8.18
- Colon - Transverse6.68
- Cervix - Ectocervix4.84
- Nerve - Tibial4.18
- Cervix - Endocervix4.1
- Fallopian Tube3.26
- Adipose - Subcutaneous3.19
- Lung2.89
- Uterus2.62
- Whole Blood2.24
- Thyroid2.24
- Breast - Mammary Tissue1.86
- Vagina1.85
- Adipose - Visceral (Omentum)1.8
- Small Intestine - Terminal Ileum1.73
- Artery - Coronary1.55
- Pituitary1.53
- Prostate1.4
- Bladder1.24
- Artery - Tibial1.16
- Ovary0.94
- Skin - Sun Exposed (Lower leg)0.94
- Esophagus - Gastroesophageal Junction0.92
- Artery - Aorta0.89
- Heart - Left Ventricle0.89
And 29 more, listed on the interactive page.
Biological processes
- GO:0071799
Cellular components
- GO:0005886
Molecular functions
- GO:0005515
Related records
Trials (326)
- 24-Hour Vaginal Dinoprostone Pessary Versus Gel for Labour Induction
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)
- A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
- A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
- A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD
- A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term
- A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
- A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus
- A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
- A Study of Laropiprant (MK-0524) in Participants With Moderate to Severe Erythematotelangiectatic Rosacea (MK-0524-155)
- A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants
- A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension
- A Study to Assess the Safety and Efficacy of Treprostinil to Facilitate Liver Transplantation in Patients With Portopulmonary Hypertension
- A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
- A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
- A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
- A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy Participants
Drugs (9)
- Alprostadil
- Asapiprant Prostanoid DP receptor antagonist
- Cloprostenol
- Dinoprost
- Dinoprostone
- Iloprost
- Laropiprant Prostanoid DP receptor antagonist
- Treprostinil
- Vidupiprant Prostanoid DP receptor antagonist